Yu. A. Rogacheva

Yu. A. Rogacheva

Auto-generated profile, based on publicly available information

Yu. A. Rogacheva

Pavlov University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2022 in The Scientific Notes of the Pavlov University
Verified
Journal Article
Open access
PDF file
ACA. M. Chekalov
A. M. Chekalov
MPMarina Popova
Marina Popova
ITI. V. Tsygankov
I. V. Tsygankov
YRYu. A. Rogacheva
Yu. A. Rogacheva
NVNikita Volkov
Nikita Volkov
AKAlexander Kulagin
Alexander Kulagin
Introduction. The risk of developing Hodgkin lymphoma (HL) with HIV infection is higher than in the general population, and the course of the disease itself is more aggressive. Currently, there is no unified approach to the treatment of HIV-related HL, and data on its epidemiology in the Russian Federation are limited.The objective was to study epidemiological characteristics, the used therapeutic tactics and the results of treatment for HIV-related HL.Methods and materials. The multicenter retrospective study included 46 patients with HIV- related HL treated in 9 centers of the Russian Federation. Descriptive statistics methods were used, the analysis of overall survival (OS) and progression-free survival (PFS) was performed using the Kaplan–Meier method.Results. HIV-related HL is more often represented by an advanced stage, B-symptoms, and extranodal lesions. The ABVD regimen was used as the first-line therapy in 60 % for HIV-related HL. The overall response to therapy was 81.6 %, and the 2-year OS and PFS were 85 % and 49 %, respectively. Factors that worsened OS were CD4+˂266 cells/mcL and general somatic status ECOG≥2.

15 March 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
MPMarina Popova
Marina Popova
YRYu. A. Rogacheva
Yu. A. Rogacheva
Background. Invasive mycoses (IM) are one of the most severe infectious complications in oncohematology. The etiological structure of IM is a rather heterogeneous group of microorganisms and undergoes changes over time. Understanding the IM etiological structure is the basis for choosing an effective IM prevention and treatment strategy.Aim. To conduct a systematic review with a meta-analysis of data on the IM etiological structure in patients of all ages receiving therapy for oncohematological diseases, including patients who underwent hematopoietic stem cell transplantation. The analytical hypothesis was the assumption of an increase in caused by rare pathogens IM proportion in the overall IM structure over the past few years. Clinical manifestations, affected organs, risk factors and outcomes were analyzed using the literature review method.Materials and methods. A systematic search was carried out for publications with data on the IM species structure available for analysis until February 10, 2022 in 3 databases (PubMed (Medline), Embase and eLibrary.ru). All IM were divided into 11 groups. The IM species structure was constructed in several patient subgroups in 2 time ranges – in studies before 2010 and after 2010, and they were compared. Results from individual studies were pooled by metaanalysis. Data from selected publications were reviewed to analyze the IM clinical manifestations, risk factors for their development and outcomes.Results. Thirty-four publications were selected using a systematic search. The meta-analysis included 43 cohorts of patients with 2771 samples of IM pathogens. The time period up to 2010 included 16 cohorts with a total number of IM pathogens of 1158 samples; in the time interval after 2010 – 27 cohorts with a total number of IM pathogens of 1613 samples. Analysis of total group showed that the proportion of rare IM among all patients increased from 29 to 39 %. In the subgroup of patients with oncohematological diseases, it increased from 28 to 33 %. For total group of patients, the in‑ crease in rare IM proportion is due to an increase in rare yeasts (from 3.0 to 4.1 %) and a significant increase in the proportion of unidentified species (from 3.2 to 19.8 %). In children, the frequency of rare IM increased from 26 to 28 % among all nosologies. For total children group, the increase in rare IM proportion is due to an increase in mucormycosis (from 1.3 to 1.6 %), rare yeasts (from 4.7 to 7.9 %) and unidentified species (from 4.5 to 12.2 %). In total adult patients group, the frequency of rare IM increased from 24 to 35 %, in adult patients with oncohematological diseases – from 23 to 40 %. For total adult patients group, the increase in rare IM proportion is due to an increase in cryptococcosis (from 1.3 to 2.4 %), hyalohyphomycosis (from 3.4 to 4.8 %), rare yeast (from 1.6 to 1.9 %) and unidentified species (from 1.9 to 16.6 %); for a group of patients with oncohematological diseases – an increase in cryptococcosis (from 1.3 to 2.1 %), rare yeast (from 1.6 to 2.6 %) and unidentified species (from 1.9 to 23.1 %). There is no specific clinical manifestations characteristic of IM, the symptoms are associated with the affected organ. Febrile fever is the only IM systemic clinical manifestation, independent of localization. The lungs were the most common IM localization. The main IM risk factors are prolonged blood cell deficiency, uncontrolled underlying disease, concomitant conditions: comorbidity, diabetes mellitus, mucositis, graft-versus-host disease, infections caused by other pathogens, and a history of IM. IM increases the risk of death, attributable mortality is variable and ranged from 13 to 72 %. The most common cause of death in oncohematological patients with IM is the progression of the underlying disease, in patients after hematopoietic stem cell transplantation – graft-versus-host disease, cardiovascular complications.Conclusion. In IM structure in oncohematological patients and hematopoietic stem cell transplant recipients, the proportion of rare IM increased markedly, mainly due to an increase in their proportion in adult patients with oncohematological diseases. The increase in rare IM proportion is mainly due to the increase in unidentified species, hyalohyphomycosis, rare yeast and cryptococcosis. Clinical manifestations are due to the localization, the main of which is the lungs. The development of IM increases the risk of death, but attributable mortality is about 50 %.

17 May 2024 in Clinical Transplantation
Verified
Journal Article
Closed access
ASAleksandr Siniaev
Aleksandr Siniaev
MPMarina Popova
Marina Popova
YRYulia Rogacheva
Yulia Rogacheva
VIValeria Ianbukhtina
Valeria Ianbukhtina
EKEgor Kulagin
Egor Kulagin
AKAlexander Kulagin
Alexander Kulagin

29 June 2019 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IMI. V. Markova
I. V. Markova
YRYu. A. Rogacheva
Yu. A. Rogacheva
MPMarina Popova
Marina Popova
AVA. G. Volkova
A. G. Volkova
KEK. A. Ekushov
K. A. Ekushov
BAB. V. Afanasyev
B. V. Afanasyev
Invasive fungal disease due to Candida spp. – Invasive candidiasis/candidaemia, is a life-threatening complication in immunosuppressed patients. The publications on epidemiology of invasive candidiasis (IC) in children after hematopoietic stem cell transplantation (HSCT) is limited. The purpose of the study was to study the epidemiology of IC in children after HSCT for the 7 years in Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation. In 2009–2016 yy have been performed 754 HSCT in children: 494 allogeneic and 260 autologous. The study was approved by the Independent Ethics Committee of the Raisa Gorbacheva Memorial Research Institute of Children's Oncology, Hematology and Transplantation. A retrospective study included 22 cases of invasive candidiasis in after HSCT. EORTC/MSG 2008 criteria were used for the diagnosis of proven invasive candidiasis as well as to evaluate response to therapy. Incidence of IC was 2.9%: allo-HSCT – 3% (n = 15), auto-HSCT – 2,7% (n = 7). The study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The etiology: Candida parapsilosis – 50%, Candida albicans – 27%, Candida krusei – 14%, Candida tropicalis – 5%, Candida dubliniensis – 4%. The most frequent underlying diseases was acute leukemia – 45% (n = 10). The median age was 8 y.o. (3 month–18 years). The median day of onset of IC after allo-HSCT was 63 days (4–243), auto-HSCT – 12 days (3–20). Febrile fever was the main clinical symptom; septic syndrome develops in 32% cases. Antifungal therapy was with echinocandins – 23%, lipid ampho B – 27%, triazole (fluconazole, voriconazole) – 32%, without therapy (due to early mortality) – 18%. Overall survival (OS) at 30 days from diagnosis invasive candidiasis was 50%. The central venous catheter (CVC) removal was the only factor significantly improved OS (70% vs 33%, p = 0,035). Incidence of Invasive candidiasis in children after hematopoietic stem cell transplantation was 2.9%. The main etiology agent was Candida parapsilosis. Invasive candidiasis infections most often affect leukemia patients, after allo-HSCT developed later than auto-HSCT. Overall survival at 30 days from the diagnosis was 50%. Removing of CVC improved overall survival in children with invasive candida infections after HSCT

1 June 2021 in The Scientific Notes of the Pavlov University
Verified
Journal Article
Open access
PDF file
YRYu. A. Rogacheva
Yu. A. Rogacheva
MPMarina Popova
Marina Popova
IMI. V. Markova
I. V. Markova
OPO. V. Paina
O. V. Paina
DSD. I. Shmidt
D. I. Shmidt
Nikolai KlimkoNikolai Klimko
Nikolai Klimko
Malassezia spp.is a commensal yeast that represents normal microflora in humans and some animals. However,Malassezia spp.can cause life-threatening invasive mycosis. Evidence on Malassezia spp. infections is limited mostly to a case reports describing disease in newborns and premature infants, because lipid infusions (total parenteral nutrition) given through central venous catheter is a major risk factor. Here, we report two cases of CNS infection caused by Malassezia species in non-neonates with acute leukemia.

14 February 2026 in Grekov's Bulletin of Surgery
Verified
Journal Article
Closed access
AAA. L. Akopov
A. L. Akopov
RMR. P. Mishra
R. P. Mishra
ASA. N. Shvetsov
A. N. Shvetsov
MPMarina Popova
Marina Popova
YRYu. A. Rogacheva
Yu. A. Rogacheva
AKAlexander Kulagin
Alexander Kulagin
INTRODUCTION. The role of surgical treatment of invasive mycoses (IM) of the lungs after hematopoietic stem cell transplantation (HSCT) and antitumor chemotherapy (ACT) in patients with oncohematological profile has not been determined. There are only isolated publications on this topic in the scientific medical literature, the presented results are contradictory, and it is difficult to use them to make decisions. MATERIALS AND METHODS. A retrospective analysis of immediate and long-term treatment results was conducted for patients who underwent ACT and/or HSCT and underwent lung resections for invasive mycosis since 2013. The indications for surgery were the absence of positive dynamics or progressive inflammatory changes in the lungs despite adequate antifungal therapy. RESULTS. The study included 13 patients, children (n=3) and adults (n=10), 11 males, with a median age of 25 years (ranging from 10 to 64 years). Diagnoses: acute leukemia in 4 patients (31 %), chronic myeloproliferative diseases in 4 patients (31 %), aplastic anemia in 3 patients (23 %), and lymphoma in 2 patients (15 %). In 11 cases (85 %), IM developed in patients after allogeneic HSCT (allo-HSCT), and in 2 cases (15 %) during ACT, with a median development time of 96 days after treatment initiation (ranging from 20 to 510 days). Neutropenia was observed in 46 % of patients (n=6), and platelet counts below 50х10 9 /L in 10 patients (77 %). Bilateral lung changes were present in 54 % of cases (n=7), unilateral lung changes in 46 % of cases (n=6). 5 pneumonectomies, 4 lower lobectomies, 2 upper bilobectomies, 2 atypical lung resections, and 1 upper lobectomy were performed; 2 out of 13 patients (15 %) underwent chest wall resection. One patient died in the early postoperative period (7.7 %). Eight patients (61.5 %) recovered from pulmonary IM with a median follow-up of 118 days (ranging from 42 to 900 days). CONCLUSIONS. Surgical treatment of IM in this patient group is possible provided that risk factors are eliminated or, more commonly, their severity is reduced (compensation of concomitant conditions, discontinuation of antitumor chemotherapy, transfusions of erythrocyte mass, and platelets). With proper selection of hematological patients with pulmonary IM, the immediate results of surgical treatment can be considered favorable.